Cyclic Nucleotide Regulation of PAI-1 mRNA Stability

IDENTIFICATION OF CYTOSOLIC PROTEINS THAT INTERACT WITH AN A-RICH SEQUENCE*

Abstract

Incubation of HTC rat hepatoma cells with the cyclic nucleotide analogue 8-bromo-cAMP results in a 3-fold increase in the rate of degradation of type-1 plasminogen activator-inhibitor (PAI-1) mRNA. Previous studies utilizing HTC cells stably transfected with β-globin:PAI-1 chimeric constructs demonstrated that at least two regions within the PAI-1 3′-untranslated region mediate the cyclic nucleotide-induced destabilization of PAI-1 mRNA; one of these regions is the 3′-most 134 nucleotides (nt) of the PAI-1 mRNA (Heaton, J. H., Tillmann-Bogush, M., Leff, N. S., and Gelehrter, T. D. (1998) J. Biol. Chem. 273, 14261–14268). In the present study, ultraviolet cross-linking analyses of this region demonstrate HTC cell cytosolic mRNA-binding proteins ranging from 38 to 76 kDa, with a major complex migrating at ∼50 kDa. RNA electrophoretic mobility shift analyses demonstrate high molecular weight multiprotein complexes that specifically interact with the 134-nt cyclic nucleotide-responsive sequence. The 50, 61, and 76 kDa and multiprotein complexes form with an A-rich sequence at the 3′ end of the cyclic nucleotide-responsive region; a 38-kDa complex forms with a U-rich region at the 5′ end of the 134 nt sequence. Mutation of the A-rich region prevents both the binding of the 50-, 61-, and 76-kDa proteins and formation of the multiprotein complexes, as well as cyclic nucleotide-regulated degradation of chimeric globin:PAI-1 transcripts in HTC cells. These data suggest that the proteins identified in this report play an important role in the cyclic nucleotide regulation of PAI-1 mRNA stability.

Footnotes

  • * This work was supported by United States Public Health Service Grant CA22729 from the National Cancer Institute (to T. D. G.) and National Research Service Award DK09437 from the National Institutes of Health (to M. T.-B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • To whom correspondence should be addressed: Dept. of Human Genetics, M4708 MSII/0618, University of Michigan Medical School, 1301 Catherine St., Ann Arbor, MI 48109-0618. Tel.: 734-764-5491; Fax: 734-763-5831; E-mail: tdgum{at}umich.edu.

  • Abbreviations:
    PA
    plasminogen activator
    PAI-1
    type-1 plasminogen activator inhibitor
    cA
    8-bromo-cAMP plus IBMX
    nt
    nucleotide
    UTR
    untranslated region
    R-EMSA
    RNA electrophoretic mobility shift analyses
    E64
    trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane
    Pefabloc®SC (AEBSF)
    4-(2-aminoethyl)-benzoylsulfonyl fluoride-hydrochloride
    poly(A)
    polyadenylic acid
    poly(U)
    polyuridylic acid
    poly(G)
    polyguanadylic acid
    poly(C)
    polycytidylic acid
    PAGE
    polyacrylamide gel electrophoresis
    pKS
    pBluescript KS
    MCS
    multicloning site
    CAT
    chloramphenicol acetyltransferase
    PCR
    polymerase chain reaction
    CRE
    cyclic AMP responsive element
    CREB
    CRE-binding protein
    CPT-cAMP
    8-(4-chlorophenylthio)-cAMP
    β2-AR
    β2-adrenergic receptor
    β-ARB
    β2-adrenergic receptor-binding protein
    bp
    base pair(s).
    • Received June 23, 1998.
    • Revision received November 6, 1998.
    Table of Contents

    Submit your work to JBC.

    You'll be in good company.